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Abstract: 
Synthetic Biology (SynBio) is an emerging scientific field which has quickly established momentum 
and visibility. Although no single definition of SynBio prevails, the field broadly encompasses the 
application of engineering principles to biology; re-designing biological materials and using them as 
new substrates to create products and entities not otherwise found in nature. This paper first 
reviews SynBio, highlighting the novel aspects of this technology. It then synthesises ethical issues 
highlighted in the literature to date and makes some initial claims that research on the ethical 
aspects of SynBio should: avoid creating a new sub-type of bioethics, concentrate on novel concepts 
and problems and be situated within a context of cooperative inter-disciplinary investigation.  
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Introduction 
The convergence of methodologies and techniques in biotechnology, chemistry and engineering has 
given rise to the emergent field of synthetic biology (SynBio), which broadly aims to re-design 
biological materials and using them as new substrates to create novel entities and products in a 
variety of contexts. SynBio has rapidly gained a presence in the literature and is attracting increasing 
research funding. The field now also appears to be moving from a phase of broad manifestos to 
defined research projects and early outputs (Rabinow & Bennett, 2009). The possible applications of 
SynBio are broad, including products for use in bioremediation, biofuels and health care. 
 
Given the convergence of methodologies and the myriad and undefined applications SynBio may 
give rise to, the presence of an ethical dimension is unsurprising. Indeed, a notable feature of this 
field is that researchers in SynBio have been keen to engage with the ethical, legal and social 
implications of their work from the outset; perhaps to avoid the problems previously experienced in 
other research domains. There have been sessions dedicated to ethical issues at all major SynBio 
conferences and several multi-disciplinary collaborations have been established and attracted 
research funding. There is also a burgeoning literature on the implications of this technology 
(Bhutkar, 2005; de Vriend, 2006; Tucker and Zilinskas, 2006; Balmer & Martin, 2008; Parens et al, 
2009; European Group on Ethics, 2009; Royal Academy of Engineering, 2009). Policy-makers have 
been engaged in SynBio for some time (European Commission 2005), yet with one exception (ETC 
Group, 2007), non-governmental organisations have not yet shown significant interest in SynBio; 
perhaps because its applications remain somewhat ill-defined. 
 
This paper will provide an overview of SynBio and its ethical implications, broadly construed. The 
scope, development and putative applications of SynBio will first be described, focussing on the 
novel aspects of this technology. The established and emerging ethical issues will then be 
synthesised. Most such issues are likely to emerge at what may be called the ‘functional’ or ‘self-
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organisation’ stage of SynBio, rather than from the core scientific research methodologies that have 
driven the development of this discipline. Bearing in mind the long-standing tension between 
bioethics and the social sciences, some initial claims will then be made as to how research on the 
implications of SynBio should proceed. These are that research on the ethics of SynBio should: avoid 
creating a new sub-type of bioethics, concentrate on novel concepts and problems and be situated 
within a context of multi-disciplinary investigation.  
 
Definitions and applications of SynBio 
Although several definitions have been suggested for SynBio (see, for example: European Group on 
Ethics, 2009; Deplazes, 2009; BBSRC & EPSRC, 2010), no single descriptor has been, or is likely to be, 
accepted by the entire SynBio research community. This diversity of views is likely due to the varying 
technical emphases and approaches prevalent in SynBio. However SynBio can broadly be thought of 
as the application of engineering principles (including abstraction, standardisation and 
modularisation) to biology, to provide a rational and systematic approach to the design or re-design 
of robust, stable, predictable and novel biological parts or systems. It is a discipline of converging 
technologies; involving engineering, biotechnology, chemistry and computational modelling, among 
others.  
 
SynBio does seem to differ in kind from the technologies it has developed from.  The novelty of this 
scientific approach is that: 
...synthetic biology starts from an integrated approach with the aim to create something 
fundamentally new. Its goal far exceeds that of conventional biotechnology. Synthetic 
biologists... aim at producing living machines or completely artificial organisms...[.] (Deplazes 
et al, 2009, p73). 
 
So although it may seem that other scientific methodologies are similar, the interests that drive 
many of the researchers working on SynBio extend beyond those encountered in ‘traditional’ 
molecular biology. SynBio brings together previously unconnected scientific disciplines; faster more 
reliable and cheaper DNA synthesis and improved computing power. The design of novel 
components, parts, systems or entities also allows for a great deal of creativity. These features 
collectively allow frontiers to be explored that were not previously thought to be feasible or 
possible, such as the creation of ‘designer genomes’ from scratch. Moreover, the ready availability of 
scientific tools also means that one does not necessarily need to have access to a laboratory 
environment to undertake SynBio work. 
 
Within SynBio there are already several distinctions as to approach, which differ depending on 
methodology, materials and objectives. To this end, various classes and groupings of SynBio are 
emerging (see, eg: Deplazes, 2009; O’Malley et al, 2008). O’Malley et al (2008) have defined three 
broad approaches to SynBio: (i) DNA-based device construction; (ii) genome-driven cell engineering 
and (iii) protocell creation; each of which is briefly discussed further below. They suggest that each 
of these approaches encompasses different views about concepts such as genetic determinism and 
complexity and each will also give rise to different issues in domains such as intellectual property. 
Characterising SynBio into these categories offers an opportunity to begin to conceive of its many 
layers and will be important to any identification, synthesis and normative determination over the 
ethical issues that will arise (Deplazes, 2009).  
 
DNA-based device construction, as its name suggests, utilises DNA synthesis as a primary tool to 
design and build deliberately engineered biological systems (O’Malley, et al 2008, p57). Natural 
complexity is removed and replaced by a catalogue of standardised parts which are then used to 
perform discrete tasks or create devices. The biological systems in which these parts and devices 
might operate are de-emphasised in favour of inter-changeability. The best known example of this 
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approach is the Registry of Standard Biologial Parts (‘BioBricks’: http://partsregistry.org), an open-
access library of standardised biological parts and devices. 
 
Genome-driven cell engineering focuses on the entire genome. The aims of this approach include 
reducing existing genomes to the minimum necessary to sustain life and synthesising whole 
genomes from scratch. These can then be transplanted into host cells to investigate functional 
attributes and develop a host ‘chassis’ to assist with eventual device implantation (O’Malley et al, 
2008, p59). This approach therefore takes a genome-centric view of biological causation. Examples 
of the synthesis approach include re-creating the 1918 pandemic flu virus through purchasing 
commercially available DNA sequences (Tumpey et al, 2005) and the synthetic genome of 
Mycoplasma genitalium (Gibson et al, 2008).  
 
Protocell creation is perhaps the most ambitious, and therefore least established, approach to 
SynBio. This approach aims to construct an artificial minimal cell and to eventually use this to 
develop novel artificial cellular systems (including artificial tissues and organs). Researchers working 
with this approach are first attempting to create many of the biological components that will be 
necessary for protocell life and investigating how they interact and function in the lab (Forster and 
Church, 2006). In 2010, the same team that created M genitalium published their claim to the first 
synthetically produced cell, in which a synthetically created chromosome was transplanted into a 
bacterial cell chassis: Mycoplasma mycoides (Gibson et al, 2010). 
 
Drawing together the various conceptions of and approaches to SynBio, a range of practical 
applications may be possible. If SynBio researchers substantiate current hype, these outputs will be 
robust, novel and will have predictable properties. Applications could include devices or parts for 
use in bioremediation, biofuel production and health care (notably biosensors, novel or better 
targeted drugs, new medical devices for tissue repair and synthetic vaccines (European Commission, 
2005)).  
 
Good progress is already being made towards some of these applications. Perhaps the best-known 
example is work on a synthetic form of amorphadiene, the precursor to the chemical compound 
artemisinin – a next-generation anti-malarial drug (Ro et al, 2006). Artemisinin is a rare naturally 
occurring plant and is therefore expensive to produce. Synthetic production of its precursor will 
enable its production costs to be reduced dramatically, hopefully providing benefits for countries 
with low resources but high malaria prevalence. However, it has also been recognised that such 
scale-up of SynBio production will affect the livelihood of those living in developing countries who 
currently harvest artemisinin (Balmer and Martin, 2008). 
 
Ethical issues arising in SynBio 
The early ethical issues arising in Synthetic Biology have been well documented (see, for example: 
Balmer and Martin, 2008; Deplazes et al, 2009) and the literature in this field continues to increase. 
There are also a burgeoning number of funded projects that aim to investigate the ethical, legal and 
social issues arising in SynBio. However these ethical deliberations remain at an early stage, with 
little substantive analysis yet emerging to address the issues in depth.  
 
As mentioned in the introduction to this paper, one feature of these early debates on SynBio is that 
lab-based researchers have taken great interest in ethical discussions. Research funders have also 
recognised the potential sensitivities of this research and many funding schemes have either 
encouraged or mandated the involvement of ethics or social science researchers (such as the UK 
research council-funded networks in synthetic biology). Policy-makers are also monitoring the field 
and several committees have been established. There have also been several early public 
engagement activities.  
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Presenting an in-depth description and analysis of all of the ethical issues arising in SynBio is beyond 
the scope of this paper (and has already been published elsewhere; see for example Parens et al, 
2009). It is however important to summarise these briefly, as they influence two other key 
questions: (i) is there anything new here? and (ii) how should deliberations over the ethical, legal 
and social aspects of SynBio proceed? This is not to say that the issues identified here are (or will 
remain) objectively contentious as they are all subject to challenge – some may disappear with 
sound oversight and control, while others might be resolved through ethical reasoning and debate.  
 
As with any ethical deliberation, various taxonomies to classify the issues in SynBio can be proposed. 
One such classification has been proposed by Parens et al (2009) – physical harms and non-physical 
harms.  
 
Like many of the debates over SynBio, reasoning about harms tends to be consequentialist (Schmidt 
et al, 2008; Swierstra and Rip, 2007); perhaps because identifying outcomes and endpoints is more 
amenable to scientific engagement than is a discussion of principles, duties or virtues which may lack 
tangibility or practical context. A consequentialist approach also naturally lends itself to 
considerations of harm, which can then provide a useful ‘hook’ into discussions over policy-making 
for SynBio.  
 
Physical harms are those which threaten the actual safety and security of humans or the 
environment. Two such harms that have been discussed at length in SynBio are biosafety and 
biosecurity (Kelle, 2009). Biosafety considers the potential negative effects of synthetic or artificial 
organisms on the environment or human beings, say for example if a synthetic entity were to be 
released beyond the laboratory and interact with or alter the environment in an unexpected way. 
While novel or highly modified organisms are unlikely to survive in an environment outside the 
laboratory or could be engineered to ensure this is not possible (Garfinkel et al, 2008), there may 
also be situations where there will be a need for trade-offs between benefits and risks. Yet biosafety 
does not solely concern the substantive issues of safety or containment, which to some extent are a 
matter of careful oversight and responsible scientific practice. Debates over biosafety also include 
determining what is ‘safe’ in SynBio (Garfinkel et al, 2008) and who should determine this. While 
there is general agreement that rigorous standards are required, there is less agreement on what 
these should be. 
 
Biosecurity issues arise over the possible uses of the products of SynBio by those who wish to 
commit harmful acts such as bioterrorism (Bugl et al, 2007). This concern has been more widely 
discussed in North America than Europe, perhaps because the USA has already seen a successful 
biological attack. Much of the concern with biosecurity arises from the relative ease of obtaining 
materials necessary for baseline SynBio research outside of the more regulated environment of a 
university or research institute. Examples such as the synthesis of the virus that led to the 1918 
influenza pandemic and the polio virus by way of procuring DNA sequences online from commercial 
providers, although undertaken by responsible scientists, illustrate that an individual with mal-intent 
or a nefarious state may be able to inflict harm to many. It also gives rise to concerns about ‘dual 
use’ problems in emerging technologies; by which the same application of SynBio could give rise to 
both beneficial and harmful consequences. There is some industrial self-oversight over sequencing 
orders, but there are concerns about whether, when or how other forms of monitoring should take 
place. 
 
One further issue which overlaps with biosecurity and biosafety as physical harms is that of 
professional ethics within SynBio. Given that SynBio research involves professionals from a range of 
scientific disciplines working together for the first time, they may come together with different 
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codes of conduct or expectations as to what constitutes responsible research. While it is important 
to recognise that researchers already appreciate the possible implications of their field, monitoring 
professional integrity may become a more pressing problem as the field advances. This also gives 
rise to questions around regulation; a consideration that is briefly returned to below.  
  
While the distinction between them is somewhat blurry, non-physical harms broadly encompass 
those aims or applications of SynBio that could harm the well-being of individuals or communities 
(Parens et al, 2009). A potential non-physical harm in SynBio is the role that humans have in creating 
new entities and how this may affect conceptions of the self and relationships to the environment 
(Royal Academy of Engineering, 2009, p43). Creating novel life forms is a key aim of SynBio and there 
has been some discussion over whether creating a novel entity such as a microorganism is indeed 
creating life or merely a biological machine (Schmidt et al, 2008). However if SynBio does move on to 
more complex applications, new entities may require evaluation as to their moral status. This could 
require a reconsideration of the concept of ‘life,’ its creation and the ‘natural,’ as well as whether 
creating life is acceptable.  
 
Creating entities from biological components or the bases of DNA could also lead to a mechanistic 
understanding of life and a de-emphasis on biological interaction in the generation of complexity. 
However, some commentators claim that while an important point of discussion, such a concern 
should not limit the development of entities such as minimal genomes (Cho et al, 1999). An 
emerging question is how the concepts of life and its creation should be used in normative reasoning 
about the development of SynBio (Deplazes et al, 2009). 
 
The fair allocation of the benefits of SynBio is another putative non-physical harm. A significant 
benefit of SynBio is that it is anticipated that the scale-up and manufacture of devices, entities or 
processes developed in the lab may not be as expensive as for other emerging technologies. This is 
because SynBio can exploit the in-built proliferation mechanisms of ‘living’ entities (Schmidt et al, 
2008). However existing issues around the necessary infrastructure to translate these technologies 
for beneficial use for all will exist for SynBio just as they do for other technologies. Deliberation is 
therefore necessary to try to establish at the outset how the scale-up of SynBio processes can be 
undertaken to deliver benefit in an equitable manner. 
 
A further possible non-physical harm from SynBio, which may give rise to a conflict with fair 
allocation, is deriving commercial benefit. Just like any other scientific discipline, there is a need to 
reward and encourage innovation in SynBio while being mindful of the restrictions that too much 
intellectual property can give rise to. Some patents are already being applied for (such as Venter’s 
Mycoplasma genitalium), while several component parts of BioBricks and the pathway to developing 
artemisinin are already patented (Henkel and Maurer 2007, cited by O’Malley et al, 2008). Concerns 
have been expressed about patent thickets (multiple patent holders) and the development of an 
‘anti-commons’ in which numerous patent owners all effectively block each other from innovating 
(Royal Academy of Engineering, 2009, p44). Some groups have suggested an outright ban on 
patenting in SynBio (ETC Group, 2007), but this may be difficult due to the technical limitations in 
differentiating SynBio products from others arising in biotechnology (Rutz, 2009). One mechanism to 
ameliorate concerns may be to offer different levels of intellectual property protection for distinct 
synthetic entities; with greater protection for more complex entities. However it is not yet certain 
how this might work in practice or in conjunction with the current patents system (Royal Academy of 
Engineering, 2009). The ‘morality clause’ in EU patent law is also likely to be relevant to SynBio (Rutz, 
2009). 
 
While these issues are far from resolved, both kinds of harm arising from SynBio might be mitigated 
through appropriate regulation, governance or oversight. However, questions will also arise as to 
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what form of regulation may be needed and who should determine this. The European Group on 
Ethics has recently observed that many applications of SynBio are covered by existing European 
regulations (European Group on Ethics, 2009). However, assuming that SynBio does give rise to 
applications (or even entities) that move beyond current mechanisms of regulation and governance, 
questions will arise as to what means of oversight are appropriate, what kind of entity should create 
them and at what level (Garfinkel et al, 2007; Weir and Selgelid 2009; Samuels et al 2009).  
 
There are various models for regulation, including legal oversight, codes of conduct, 
professionalization (Weir and Selgelid, 2009) or self-regulation. Each of these has benefits and 
problems: legal oversight can provide clarity but can be inflexible in light of scientific advances. 
Codes of conduct clearly stipulate responsibilities but can be difficult to monitor or enforce. 
Professionalization provides a good balance of internal and external regulation and collective 
responsibility, yet such a model is somewhat unusual for scientists working in biology. Self-
regulation allows significant scientific freedom but may not engender public confidence (BBSRC & 
EPSRC, 2010, p42) and previous attempts at self-regulation in SynBio have failed. The unknown risks 
of SynBio will also pose regulatory challenges (BBSRC & EPSRC, 2010, p71). 
 
Ultimately, a combination of regulatory models will likely be necessary for SynBio. However the 
emphasis or ‘starting point’ for such a framework will also need to be debated. Parens et al (2009) 
distinguish between ‘precautionary’ and ‘proactionary’ frameworks, although not all scholars believe 
it is valid to conceive of these as necessarily opposing approaches (personal communication, 
Professor Andrew Stirling, 25 November 2009). However leaving this concern to one side, a 
proactionary approach instead starts from a perspective of enthusiasm for the emerging technology. 
Supporters of this framework believe that a new technology should be considered safe and 
beneficial until proven otherwise – with the burden of proof on those who wish to slow the 
development of the technology (Parens et al, 2009, p18). A proactionary approach will maximise 
research freedom and commercial benefit to drive innovation and will involve minimal oversight. 
 
A ‘precautionary’ approach would support a conservative approach to the development of a new 
technology until it is proven to be safe. This would involve the stricter of the regulatory models 
described above. While a precautionary approach to oversight of new and emerging technologies 
has tended to be criticised in bioethics literature, the nuances and uses have been defended in other 
domains such as law (Fisher, 2007). Additionally, Schmidt et al (2008) have reported that some 
scientists believe that the precautionary principle should have a role in debates over SynBio, 
particularly as we do not yet know what applications this technology may give rise to. Multi-
disciplinary engagement specific to the putative benefits and harms of SynBio may help advance this 
debate. 
 
How should ethical deliberations on SynBio proceed? 
Given their diversity, bringing these various issues together to derive an ‘ethics of SynBio’ is not 
easy. Indeed, this may not even be appropriate. In this final section, three claims will be made about 
the future of ethical deliberation on SynBio. Research on the ethical aspects of SynBio should: (1) not 
lead to another sub-type of bioethics; (2) concentrate on novel concepts and problems; and (3) be 
situated within a context of cooperative inter-disciplinary investigation. 
 
(1) Research on the ethics of SynBio should not lead to another sub-type of bioethics 
A significant question arising in ethical analyses of all new technologies is whether there is anything 
specific to that technology which would warrant a distinct methodology for bioethical inquiry. To 
this end, bioethics already features sub-disciplines such as genethics, nanoethics and neuroethics. 
Some have argued that there is little about SynBio that would warrant another methodology. For 
example, Parens et al (2008, p1449) have argued that “further balkanization of bioethics would be a 
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mistake… [Considering] the convergence of scientific investigations [in SynBio], it is not logical to 
separate the associated ethical enquires.” This sentiment has also been echoed by SynBio 
researchers (Schmidt et al, 2008). As an alternative, Parens et al (2008) claim that we instead need 
to be better able to address existing ethical questions in new scientific contexts than to derive a 
whole new sub-genre of bioethics. The challenges are how to achieve this and whether it would lead 
to anything interesting; points also considered at (2) below. 
 
However it has also been argued there is something about SynBio that sets it apart from previous 
debates in bioethics. There have been claims that analogies to past debates have their limits (Boldt 
& Müller 2008; Schmidt et al, 2008), that “synthetic biology sets these issues in a new context” and 
goes beyond previous technologies (Deplazes et al, 2009, p66), that the socio-political context in 
SynBio is different (Lentzos, 2009) and that “something new and important is happening” (Balmer 
and Martin, p4, p29).  
 
SynBio certainly has novel aspects, for example its scope for scientific creativity, the open-ended 
nature of what might be created and the potentially large scale of production. It also features a 
novel convergence of technologies and disciplines. But carving out another new sub-discipline could 
lead to a re-hashing of previous debates and further fragmenting a small discipline that is still finding 
its place in academe. 
 
As we have a diversity of theoretical approaches to bioethics, so too should these prevail in 
deliberations over SynBio. No single ethical framework should prevail as this could stifle the breadth 
of arguments and conceptual analysis that would otherwise be possible – the perspectives of virtue 
ethics and duties-based approaches to the issues raise by creating life may well lead in different 
directions. Differing theoretical approaches are likely to lead to different arguments which can then 
be weighed against each other. This will necessitate an examination of the relevant issues or 
principles arising, rather than merely assessing the specific features of the technology (Swiestra and 
Rip, 2007). The goal needs to be to avoid scholarship that is too general or abstract to say anything 
meaningful about SynBio. Of course, as research continues it may be that a sub-discipline does 
emerge; but this would have been via an organic process of characteristic reasoning and 
argumentation over SynBio rather than an up-front proclamation. 
 
(2) Bioethics research in SynBio should concentrate on novel concepts and problems 
Prima facie, this claim seems obvious. After all, no research of any kind would be worth doing if it did 
not produce something novel. However there is some merit behind this statement as it applies to 
SynBio, in spite of claim (1) above. This claim is more about the substance of the inquiry rather than 
the taxonomy of the discipline.  
 
Ethics researchers can either adopt an approach that applies previous genetic and biotechnology 
debates to SynBio (which may lead to reproducing existing discourse in a new context), or they can 
break new ground by developing and reasoning around interesting new questions. The latter can be 
drawn from what it is that SynBio researchers themselves claim is new about this scientific research - 
it involves taking the above claim of Parens et al (2008) but making sure that the questions 
answered are novel. To give an example, approaching the question of just distribution of the 
benefits of SynBio could lead to a re-consideration of existing problems in resource allocation. But it 
could also lead to new questions around managing potentially limitless synthetically produced 
resources, or allocating new living entities – should any form of moral status affect how a new entity 
is distributed?  
 
Bioethics research within SynBio could therefore become one interesting exemplar for ethical 
analysis and conceptual reflection on emerging technologies. This way the issues can be scoped out 
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and room made for sound analysis and normative reasoning (particularly surrounding novel 
concepts and problems) while avoiding a superficial listing of the issues that arise or defining 
priorities and methodologies for ethics research too narrowly. 
 
(3) Ethical analyses of SynBio need to be inter-disciplinary 
This claim is perhaps the most difficult to defend without collapsing into the history, methodology 
and validity of the discipline of bioethics and its relationship to ethical theory, law and social science. 
To state that researchers in bioethics should not ignore the work of their colleagues in law and social 
science is obvious, yet appears glib without further substantiation. The claim being made here is a 
modest one: it is that the status quo in SynBio offers an excellent opportunity not only to determine 
what is required to substantially reason around the novel ethical issues arising, but also to consider 
how ethical, legal and social science approaches might best integrate to provide a rich reflection on 
SynBio and its future development. Achieving this will not be easy given that bioethics is often 
caricatured as a ‘four principles’ mantra or a consequentialist tick list. Likewise, bioethicists are 
surely guilty of misunderstanding the purpose and place of social science approaches, not least their 
puzzlement at the lack of normativity. It would be interesting and potentially very useful if 
academics in these related but mutually suspicious disciplines were able to use SynBio as something 
of a case study to gain a deeper understanding of the academic aims and conventions of their 
colleagues; rather than taking a ‘straw man’ example and using it to claim that one disciplinary 
approach trumps another. Yearley (2009) arguably fails to do this when he cites a short ‘four 
principles’ ethics paper as evidence to debunk the utility of the entire bioethics approach to SynBio.   
 
Conclusion 
Synthetic Biology research is continuing to grow and develop. As the applications of this emerging 
and converging approach become clearer, so too will the foci for ethical, legal and social 
deliberations that are required. A positive aspect of the debate to date is that it offers an excellent 
opportunity to examine the development of a new technology and shape wider reflection on its 
implications from the bottom-up, rather than assessing the problems that have arisen ‘after the 
fact’. The engagement of scientists in SynBio is particularly welcome in this respect. 
 
Therefore, research on the ethical, legal and social aspects of SynBio needs to: concentrate on novel 
concepts and problems, avoid simply segmenting a new sub-type of bioethics and be situated within 
a context of multi-disciplinary investigation. These three claims certainly require further work and 
are certainly open to rebuttal. However if they are prima facie valid then good attempts can be 
made to identify the substantive issues, principles and themes at stake in SynBio as well as 
encourage sound cooperation among researchers. 
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